Prime Highlights
- RBC Capital’s Outperform rating and $80 target back GE HealthCare’s stronger commercial track record and growing order backlog since its 2023 split from General Electric .
- GE HealthCare used SIIM 2026 to put Genesis Radiology Workspace and InteleShare front and center, staking its claim in cloud-based enterprise imaging .
Key Facts
- Heavier R&D spending post-2023 was a key factor in RBC Capital’s decision to rate GE HealthCare positively.
- Both platforms give clinical teams remote scan access and secure image sharing across facilities, reducing delays in time-critical care.
Background
RBC Capital picked up coverage of GE HealthCare Technologies Inc. this week, assigning an Outperform rating and an $80 price target on the back of a solid growth outlook for the rest of 2026.
The firm pointed to a strong risk-reward profile, noting that GE HealthCare has stepped up research and development spending and sharpened its commercial execution since splitting from General Electric in 2023.
A healthy order backlog, RBC Capital added, puts the company in a good position to post stronger growth later this year.
GE HealthCare also drew attention earlier this month when it announced plans to showcase its latest cloud-enabled imaging technologies at the SIIM 2026 Annual Meeting. The company brought two products to the fore, Genesis Radiology Workspace and InteleShare.
Genesis is a regulatory-approved viewing tool that lets doctors access medical scans remotely and compare current images against earlier ones with ease.
InteleShare works as a secure cloud platform built to move medical images safely between hospitals and clinics without compromising data integrity.
Scott Miller, Chief Executive of Solutions for Enterprise Imaging at GE HealthCare, said connected cloud technologies can help providers cut through inefficiencies and streamline how imaging workflows run day to day.
GE HealthCare operates across four business divisions, covering Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, serving a broad range of medical technology and digital health needs. The company trades on the NASDAQ under the ticker GEHC.
